Table 2.
Baseline characteristics of the 293 patients
| Characteristic | Patients (n = 293) |
|---|---|
| Demographics | |
| Sex (M/F) | 241/52 |
| Age (years), mean (s.d.; range) | 49 (12; 18–78) |
| Body mass index (kg/m2), mean (s.d.; range) | 22.8 (3.3; 10.5–33.8) |
| Biochemical data | |
| Alanine aminotransferase (IU/L), median (IQR) | 35 (23–54) |
| Aspartate aminotransferase (IU/L), median (IQR) | 33 (25–47) |
| Gamma glutamyl transpeptidase (IU/L), median (IQR) | 59 (35–122.5) |
| Total bilirubin (IM/L), median (IQR) | 12.8 (9.5–18.3) |
| Platelet count, 103/mm3, median (IQR) | 177 (125–241) |
| Albumin (g/L), median (IQR) | 41.3 (38.4–44.3) |
| International normalized ratio, median (IQR) | 1.05 (1.00–1.11) |
| Liver specimens | |
| Biopsy | 220 (75.1%) |
| Liver resection | 73 (24.9%) |
| Etiology | |
| HBV | 242 (82.6%) |
| HCV | 11 (3.8%) |
| HBV+HCV | 2 (0.7%) |
| Autoimmune hepatitis | 10 (3.4%) |
| Drug induced | 5 (1.7%) |
| Alcohol induced | 3 (10.3%) |
| NAFLD | 15 (5.1%) |
| Primary sclerosing cholangitis | 5 (1.7%) |
| Fibrosis | |
| F0 | 22 (7.5%) |
| F1 | 55 (18.8%) |
| F2 | 59 (20.1%) |
| F3 | 65 (22.2%) |
| F4 | 92 (31.4%) |
| Inflammation grade | |
| A0 | 11 (3.8%) |
| A1 | 122 (41.6%) |
| A2 | 64 (21.8%) |
| A3 | 96 (32.8%) |
HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; IQR, interquartile range